Cargando…
Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy
INTRODUCTION: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as strong as one BNT162b2 vaccine dose. Nevertheless, some aspects require further investigation to better understand the immunogenicity of one vaccine dose among infected individuals. Thus, we evaluated...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715151/ https://www.ncbi.nlm.nih.gov/pubmed/34964938 http://dx.doi.org/10.1007/s40121-021-00582-9 |
_version_ | 1784624077323894784 |
---|---|
author | Homan, Tobias Fortunato, Francesca Corso, Gaetano Lopalco, Pier Luigi Prato, Rosa Martinelli, Domenico |
author_facet | Homan, Tobias Fortunato, Francesca Corso, Gaetano Lopalco, Pier Luigi Prato, Rosa Martinelli, Domenico |
author_sort | Homan, Tobias |
collection | PubMed |
description | INTRODUCTION: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as strong as one BNT162b2 vaccine dose. Nevertheless, some aspects require further investigation to better understand the immunogenicity of one vaccine dose among infected individuals. Thus, we evaluated how previous SARS-CoV-2 infection may influence the humoral immunity after a single Pfizer BNT162b mRNA vaccine dose in a sample of healthcare workers (HCWs). METHODS: As part of the routine surveillance activity conducted among HCWs of the Policlinico Riuniti Foggia Hospital (Apulia region, Italy), we conducted a retrospective serosurvey in the period January–March 2021. We compared specific antibody titres (anti-spike IgGs measured by enzyme-linked immunoassay, ELISA) after SARS-CoV-2 infection and after the first dose of the BNT162b2 vaccine, analysing the impact of sex, age, time since infection, and presence of symptoms on the humoral response. RESULTS: We included in the study 58 HCWs (mean age 44.1 years, 48.2% male) with anti-spike IgG titres available before and after the first BNT162b2 vaccine dose. Among these, we observed higher titres in previously infected cases (N = 21) than in COVID-19-naïve subjects (N = 37) (medians 1510 vs. 0.68; p < 0.001). A statistically significant difference in anti-spike IgG titres was also observed among previously infected HCWs before vaccine dose in comparison with post-dose infection-naïve HCWs (medians 18.37 vs. 0.68, p < 0.001). Among infected individuals, no differences by sex, age, or time since infection were reported (p > 0.05). Post-dose titres of symptomatic and asymptomatic infected HCWs slightly differed (medians = 1900 vs. 1090; p = 0.048). CONCLUSION: Our data support the viable hypothesis of a single-dose vaccine regimen in individuals with a history of COVID-19, but no conclusion on duration of protection in this group can be drawn from our study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00582-9. |
format | Online Article Text |
id | pubmed-8715151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-87151512021-12-29 Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy Homan, Tobias Fortunato, Francesca Corso, Gaetano Lopalco, Pier Luigi Prato, Rosa Martinelli, Domenico Infect Dis Ther Brief Report INTRODUCTION: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as strong as one BNT162b2 vaccine dose. Nevertheless, some aspects require further investigation to better understand the immunogenicity of one vaccine dose among infected individuals. Thus, we evaluated how previous SARS-CoV-2 infection may influence the humoral immunity after a single Pfizer BNT162b mRNA vaccine dose in a sample of healthcare workers (HCWs). METHODS: As part of the routine surveillance activity conducted among HCWs of the Policlinico Riuniti Foggia Hospital (Apulia region, Italy), we conducted a retrospective serosurvey in the period January–March 2021. We compared specific antibody titres (anti-spike IgGs measured by enzyme-linked immunoassay, ELISA) after SARS-CoV-2 infection and after the first dose of the BNT162b2 vaccine, analysing the impact of sex, age, time since infection, and presence of symptoms on the humoral response. RESULTS: We included in the study 58 HCWs (mean age 44.1 years, 48.2% male) with anti-spike IgG titres available before and after the first BNT162b2 vaccine dose. Among these, we observed higher titres in previously infected cases (N = 21) than in COVID-19-naïve subjects (N = 37) (medians 1510 vs. 0.68; p < 0.001). A statistically significant difference in anti-spike IgG titres was also observed among previously infected HCWs before vaccine dose in comparison with post-dose infection-naïve HCWs (medians 18.37 vs. 0.68, p < 0.001). Among infected individuals, no differences by sex, age, or time since infection were reported (p > 0.05). Post-dose titres of symptomatic and asymptomatic infected HCWs slightly differed (medians = 1900 vs. 1090; p = 0.048). CONCLUSION: Our data support the viable hypothesis of a single-dose vaccine regimen in individuals with a history of COVID-19, but no conclusion on duration of protection in this group can be drawn from our study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00582-9. Springer Healthcare 2021-12-29 2022-02 /pmc/articles/PMC8715151/ /pubmed/34964938 http://dx.doi.org/10.1007/s40121-021-00582-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Brief Report Homan, Tobias Fortunato, Francesca Corso, Gaetano Lopalco, Pier Luigi Prato, Rosa Martinelli, Domenico Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title | Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title_full | Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title_fullStr | Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title_full_unstemmed | Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title_short | Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy |
title_sort | effect of previous sars-cov-2 infection on antibody response to a single immunization with the pfizer bnt162b mrna vaccine among healthcare workers in foggia, italy |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715151/ https://www.ncbi.nlm.nih.gov/pubmed/34964938 http://dx.doi.org/10.1007/s40121-021-00582-9 |
work_keys_str_mv | AT homantobias effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly AT fortunatofrancesca effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly AT corsogaetano effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly AT lopalcopierluigi effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly AT pratorosa effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly AT martinellidomenico effectofprevioussarscov2infectiononantibodyresponsetoasingleimmunizationwiththepfizerbnt162bmrnavaccineamonghealthcareworkersinfoggiaitaly |